Bleomycin Sulfate

Catalog No.S1214 Synonyms: NSC125066

Bleomycin Sulfate Chemical Structure

Molecular Weight(MW): 1512.62

Bleomycin Sulfate is a glycopeptide antibiotic and an anticancer agent for squamous cell carcinomas (SCC) with IC50 of 4 nM in UT-SCC-19A cells.

Size Price Stock Quantity  
USD 170 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 13 Publications

1 Customer Review

  • AACR 2011 Bleomycin Sulfate purchased from Selleck.

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Description Bleomycin Sulfate is a glycopeptide antibiotic and an anticancer agent for squamous cell carcinomas (SCC) with IC50 of 4 nM in UT-SCC-19A cells.
In vitro

UT-SCC-12A and UT-SCC-12B are both more resistant to Bleomycin sulfate with IC50 of 14.2 nM and 13 nM, respectively. [1] Alveolar macrophages incubated with 0.01 μg/mL to 1μg /mL Bleomycin sulfate for 18 hours secretes significantly more fibroblast growth factor than macrophages incubated without Bleomycin sulfate. Macrophages stimulated with Bleomycin sulfate continues to produce significant amounts of fibroblast growth factor even after Bleomycin sulfate is removed and replaced with fresh (Bleomycin sulfate-free) media. Fibroblast growth factor secretion by Bleomycin sulfate-stimulated alveolar macrophages is inhibited by cycloheximide, and the 5-lipoxygenase inhibitors NDGA (nordihydroguaiaretic acid) and BW755c, indicating not only a requirement for protein synthesis but also for metabolites of the 5-lipoxygenase pathway of arachidonic acid metabolism for full expression of activity. [2] Bleomycin sulfate (400 µg/mL) incubation for 24 hours decreases the viability of NTera-2 cells, and increases caspase-3, -8 and -9 activities, Bax and cytoplasmic cytochrome c levels and decreases Bcl-2 levels. [3] In terms of unstable aberrations, the clastogenic effect of Bleomycin sulfate on ADIPO-P2 cells persists for at least 10 days after exposure. Bleomycin sulfate-induced telomere instability in mammalian cells persists for several generations after exposure. Moreover, the appearance of telomere fusions in Bleomycin sulfate-exposed cells 10 days after treatment suggests that Bleomycin sulfate can induce delayed telomere instability. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
F98 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPnRmYx6oDVMUCwNEDPxG1? NHK5UnIzPCCqwrC= NWfmV3dicW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? MmfDNlYxQDh5MUG=
POLK WT NFu4T5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIftNZdKSzVyPUGxMlfjiIoEsfMAjVEvP8LizszN M2Kze|I3ODNzNECw
POLK KO M4PtV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXUTWM2OD12LkCz5qCKyrIkgJmxMlkzyqEQvF2= NEi4TlgzPjB|MUSwNC=>
POLK CD M3Xmdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoKwTWM2OD13LkW55qCKyrIkgJmxMlAxyqEQvF2= NXPoSWllOjZyM{G0NFA>
RLE/Abca3 M2DWcmZ2dmO2aX;uJGF{e2G7 MXiwMlTDqM7:TR?= M{jqV|E1PMLiaB?= MVrpcoR2[2W|IHGgcY9zeGixbH;nbYNidCClaHHu[4Uh\nKxbTDldIl1cGWuaXHsMYxqc2VibX;ydIhwdG:peTD0c{BiKHerZHWsJJNxemWjZD3veZQhdW:{cHjvcI9ogcLi NYn0eoFoOjV5NkC1N|g>
PMCs MULGeY5kfGmxbjDBd5NigQ>? M4\yXFAvOeLCk{NCpO69\y:vbB?= NFXWT3AzPMLiaB?= NEfiNVFk[XW|ZYOgZUBld3OnLXTldIVv\GWwdDDpcoNz\WG|ZTDpckB1cGVicILveIVqdiCuZY\lcEBw\iClb3zsZYdmdi2LwrC= M4TOW|I2PTl3NkSy
PMCs MkLGSpVv[3Srb36gRZN{[Xl? Mn3qNE4zyqEQvHevcYw> MlvuNlTjiJN5MtMgbC=> MoHCbY5lfWOnczDpcoNz\WG|ZYOgbY4hfmmvZX70bY4h[W6mIN8xMXNOSSCycn;0[Ylv M{XwUlI2PTl3NkSy
PMCs M1rPTWZ2dmO2aX;uJGF{e2G7 MorZNE4zyqEQvHevcYw> NWiw[41TPzJiaB?= M{WwRolv\HWlZYOg[IVkemWjc3XzJIlvKGO7dH;r[ZJifGmwLUigZY5lKEVvY3HkbIVzcW5icILveIVqdg>? MmLUNlU2QTV4NEK=
PMCs MVPGeY5kfGmxbjDBd5NigQ>? NX71R3NwOC5{wrFOwIcwdWx? MV2xNk8zPC92ODDo M4fndYlv[3KnYYPld{Bk\WyuIH3p[5JifGmxbh?= M1rjWFI2PTl3NkSy
IMR-32 NXfDTY9jT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDVNoVLPy534pkSNVIxKML3Zz;tcC=> M2HPWVEz6ojUNEigbC=> MU\JR|UxRTZyINM1[{9udCCjdDD0bIUh\W6mIH;mJFI1KGi{czDv[kBqdmO3YnH0bY9v NX32cXZIOjV3M{[zOFU>
HT1080 NEPrfIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXOWnQyKM7:TR?= NWHFRnFuOjRiaNMg MX7s[YFleyC2bzDhJGczN01iZHXsZZk> NVLoV3NKOjV3MUi5OlE>
HT1080 NVL4fnltTnWwY4Tpc44hSXO|YYm= M1ruW|Eh|ryP NVfMUY5JOjRiaNMg M{W2bYlv\HWlZYOgZUBxd3SnboSg[4xw[mGuIFTORUBl[W2jZ3WgdoV{eG:wc3W= M{LjeFI2PTF6OU[x
HDFn MVLDfZRwfG:6aXPpeJkhSXO|YYm= NHPPTWY4OiCq NHrZeYVKSzVyPUmuN|EmyqB? MkPCNlUzPzZ5OUK=
THP-1 MnHHR5l1d3SxeHnjbZR6KEG|c3H5 NIn4VlQ4OiCq Ml7ZTWM2OD12Lke3KS=> NV3wXHRzOjV{N{[3PVI>
HT-29 MlzuR5l1d3SxeHnjbZR6KEG|c3H5 NH\LUXQ4OiCq M2q2c2lEPTB;MUGuOFkm MV2yOVI4Pjd7Mh?=
HCT116  NXXNNpUyS3m2b4TvfIlkcXS7IFHzd4F6 M{TNS|czKGh? Moj2TWM2OD1zMT6zOEU> NEnvXY4zPTJ5Nke5Ni=>
A431 MmrHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYC1NE0zODBiSWW= MX[0PQKBkWh? NH;ZcmpqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 NGjQUXgzPTFyMUK5PS=>
T24 NXrsSXRPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;4[FUxNTJyMDDJWS=> MlruOFjjiImq M{fkeolvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> NEHGR2wzPTFyMUK5PS=>
AY-27  M2rMdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkmyOVAuOjByIFnV MYS0PQKBkWh? M1T4TolvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> NXn0dINUOjVzMEGyPVk>
A549 NEXMc2tHfW6ldHnvckBCe3OjeR?= NVXpSI9XOSEEtXevcWzDqA>? NVrFOFFtOC12ODDo MlrRbY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mxsBQWE8EoH3SUmE> MXSyOFk3OzZ|NR?=
MLE12 MknaSpVv[3Srb36gRZN{[Xl? MlvaNUDDvWdxbV|CpC=> NHvjZ5oxNTR6IHi= MYLpcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ib3dCpG9RVsLibWLORS=> NIDTeFkzPDl4M{[zOS=>
Jurkat M125d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4W5dlIx6oDLzszt MXGyOQKBkWkEoB?= MkDtZZJz\XO2czD0bIUh[2WubDDjfYNt\SCjdDD0bIUhTzJicHjhd4U> M1W1R|I1QTF4OEmz
HeLa  NIPmOYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrtSZh5UUN3ME2xNE4zyqEQvF2= NF7E[VkzPDd|MkO5Oy=>
C18-4 M1TqRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUWwMVExOCEQvF2= NGDaN3VqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 M{\2blI1PTdzOUiy
BMG-1  NWmyOGZQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HRT|QxNzhywrFOwIcwdQ>? MYGzxsBp M2nnb4lvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> NUDrdlN7OjN7ME[3NlY>
A459 MmjwRZBweHSxc3nzJGF{e2G7 MlHRNVAhdVV? MXK0PEBp NGfrcXhqdmS3Y3XzJIFxd3C2b4Ppdy=> MlPENlM6ODJ5Nk[=
MOCK NU\GSpVpSXCxcITvd4l{KEG|c3H5 M1nZe|ExKG2X MlfrOFghcA>? Mn:2bY5lfWOnczDhdI9xfG:|aYO= Mn3SNlM6ODJ5Nk[=
MMP1 M2fSR2Fxd3C2b4Ppd{BCe3OjeR?= M1ntbFExKG2X NVLJ[2o5PDhiaB?= NVzwOYI5cW6mdXPld{BieG:ydH;zbZM> MXeyN|kxOjd4Nh?=
A549 NV20O3lVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUOyNFAh|ryP NWq3d2NNOjRiaNMg MnnR[IVkemWjc3XzJINmdGxidnnhZoltcXS7IIPp[45q\mmlYX70cJk> NFHBRoIzOzhyNUe5Ny=>
HCT-116 MXLBdI9xfG:|aYOgRZN{[Xl? M33ON|MwPy53L{G1JO69\y:vbB?= NXHRVWh1PDhiaB?= MkfmdoVlfWOnczD0bIUhdGW4ZXygc4YhSkyKIHH0JIhq\2hiY3;uZ4VvfHKjdHnvci=> MWCyN|cxQDZ4OB?=
HeLa MX\BdI9xfG:|aYOgRZN{[Xl? Mlq5N{84NjVxMUWg{txoN22u NV3Y[4ZoPDhiaB?= Mm\sdoVlfWOnczD0bIUhdGW4ZXygc4YhSkyKIHH0JIhq\2hiY3;uZ4VvfHKjdHnvci=> MYmyN|cxQDZ4OB?=
HCT116 NFnreY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPObpVpOC1zMECg{txoN22u MlHxOFghcA>? MWjpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 NGnJUm4zOzVzOEKwNS=>
NCM460 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXmwMVExOCEQvHevcYw> MoDQOFghcA>? MW\pcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 MoXBNlM2OTh{MEG=
NT2  Mm\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TQPVI1KGkEoB?= MmDQUGQ2OD12MEFihKnDvWdxbXy= M33EPFI{Ozh4NEKw
NT2  Mm\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVG0PEBp MlrFUGQ2OD1zMECgxtVoN22u NHLJUlkzOzN6NkSyNC=>
NT2  NXq0bFd6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrsVFNbPzJiaB?= NX;EZolsVER3ME2yNQKBkcL3Zz;tcC=> MUKyN|M5PjR{MB?=
NT2  NVvK[4RxSXCxcITvd4l{KEG|c3H5 MmjoOFAx6oDLwsXnM41t NGKyN3IzPCCqwrC= M4XETIlv\HWlZYOgd4lodmmoaXPhcpQhcW6lcnXhd4V{KGmwIHPhd5Bie2VvMzy4MFkh[WO2aY\peJnDqA>? MmrzNlM{QDZ2MkC=
NTera-2 M3rn[WZ2dmO2aX;uJGF{e2G7 M17VVlEzOCEQvHevcYw> NVnw[Wx3PzJiaB?= NU\0PVg4e2mpbnnmbYNidnSueTDpcoNz\WG|ZYOgPE1qe2:ycn;zeIFv\SCuZY\lcJM> MUGyNlgzPTN3NR?=
NCCIT NGDyNndHfW6ldHnvckBCe3OjeR?= MkjUNVIxKM7:Zz;tcC=> NELHd3A4OiCq NUHaZ3Vpe2mpbnnmbYNidnSueTDpcoNz\WG|ZYOgPE1qe2:ycn;zeIFv\SCuZY\lcJM> MXGyNlgzPTN3NR?=
NTera-2 NEPBfGxHfW6ldHnvckBCe3OjeR?= NFvROJQyOjBizsznM41t NUTjdmFRPzJiaB?= M4DuTpNq\26rZnnjZY51dHliaX7jdoVie2W|IGTCRXJUKGyndnXsdy=> NWDYUWJFOjJ6MkWzOVU>
NCCIT MULGeY5kfGmxbjDBd5NigQ>? MkXFNVIxKM7:Zz;tcC=> NWjiRldZPzJiaB?= NILMVIF{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczDURmFTWyCuZY\lcJM> M{fDVVIzQDJ3M{W1
NCCIT MYXGeY5kfGmxbjDBd5NigQ>? MYqxNlAh|rypL33s M{P2S|czKGh? MYPzbYdvcW[rY3HueIx6KGSnY4LlZZNmeyCJU1igcIV3\Wy| M2T4PFIzQDJ3M{W1
NTera-2 NHTtfVVHfW6ldHnvckBCe3OjeR?= NVvMOYh[OTJyIN88[{9udA>? MWq3NkBp MWPzbYdvcW[rY3HueIx6KGmwY4LlZZNmeyCScn;0[YlvKGOjcnLvcpltKGyndnXsdy=> M125bVIzQDJ3M{W1
NCCIT M17kbmZ2dmO2aX;uJGF{e2G7 MmDFNVIxKM7:Zz;tcC=> MXq3NkBp M4nEWJNq\26rZnnjZY51dHliaX7jdoVie2W|IGDyc5RmcW5iY3HyZo9vgWxibHX2[Yx{ NF7XVmUzOjh{NUO1OS=>
NTera-2 MYPGeY5kfGmxbjDBd5NigQ>? MmrGNVIxKM7:Zz;tcC=> MYe3NkBp NW\FTGZNe2mpbnnmbYNidnSueTDpcoNz\WG|ZYOgUHBQKGyndnXsdy=> M2LtTlIzQDJ3M{W1
NCCIT NXywbGpQTnWwY4Tpc44hSXO|YYm= M4Pk[lEzOCEQvHevcYw> MUS3NkBp NV3pco9ve2mpbnnmbYNidnSueTDpcoNz\WG|ZYOgUHBQKGyndnXsdy=> NXO1T2g6OjJ6MkWzOVU>
MDA-MB-468 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULlU5c6OOLCk{KwNOKh|rypL33M NX3oSYtsOjRiaB?= M17UVYlvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> MUOyNlgyQTF7Nh?=
231-H2N NIPyfINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlP6NQKBmzJyMNMg{txoN22O M3HxOVI1KGh? MnL6bY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> NYD3N5pWOjJ6MUmxPVY>
A549  M2nCOmZ2dmO2aX;uJGF{e2G7 MkjmNlAxNzRyMDFOwG0> M1X0SZJme3WudIOgbY4h[SCmb4PlMZJme3CxboPpeoUhcW6lcnXhd4UhcW5iUl;T M3zhTFIzPzd|Nkm3
A549  M3rGOWZ2dmO2aX;uJGF{e2G7 NGPtd4wxNTRyMDFOwG0> Mn\RNk01QCCq M2DSWYNifXOnczDtc5JmKG22RF7BJJRp[W5iblTORUBl[W2jZ3W= M4rwN|IzPzd|Nkm3
A549  MV\GeY5kfGmxbjDBd5NigQ>? NU\YWGxsOTByIN88UeKh MV2w5qCUPDhiaB?= MoHTZ4F2e2W|IHPhd5Bie2VvMzDhZ5RqfmG2aX;u MmrpNlI4PzN4OUe=
A549  NIj4b3hHfW6ldHnvckBCe3OjeR?= MoqyNVAxKM7:TdMg M32yclDjiJN2ODDo M1rwOoNifXOnczDQT2QyKGOuZXH2ZYdm NWr4OpFTOjJ5N{O2PVc>
A549  MWrGeY5kfGmxbjDBd5NigQ>? M1PwcVExOCEQvF5CpC=> M3rtOVDjiJN2ODDo NYe3dGU3[2G3c3XzJI1qfG:laH;u[JJq[WxibH;jZYxqgmG2aX;uJI9nKEKjeB?= M3fRXVIzPzd|Nkm3
A549  NVjqbJhyTnWwY4Tpc44hSXO|YYm= MlfYNVAxKM7:TdMg M4HtdFDjiJN2ODDo MoDp[IVkemWjc3XzJG1OWCCjbnSgRXRRKGyndnXsdy=> MkixNlI4PzN4OUe=
MCF-7/Her-18  MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLUVJgxNjR{LUG3NFAh|rypL33M M2rtcFI1KGh? MVPpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 M3\kXlIzPjJzNEC0
MCF-7 MlLLVGRVN1CFSTDUdoVifG2nboS= MmrkNE4zPSEQvHevcYwv M3HrVlEuPCCq MXHzbI94eyC|aXfubYZq[2GwdDCoVOKhRCByLkC1LUBkgXSxdH;4bYMh\W[oZXP0 M2TC[lIzPTlzMki0
MDA-MB-231 MoPvVGRVN1CFSTDUdoVifG2nboS= NIq0XmcxNjJ3IN88[{9udC5? NF7kWogyNTRiaB?= NH;mbW9{cG:5czDzbYdvcW[rY3HueEApWMLiPDCwMlA2MSCleYTveI95cWNiZX\m[YN1 NHrIN3kzOjV7MUK4OC=>
MDA-MB-235  NH[zNpBRTFRxUFPJJHRz\WG2bXXueC=> NIrWN3YxNjJ3IN88[{9udC5? NWDoUY1KOS12IHi= MUXzbI94eyC|aXfubYZq[2GwdDCoVOKhRCByLkC1LUBkgXSxdH;4bYMh\W[oZXP0 M2[1OFIzPTlzMki0
MCF-7 NHTQb4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUi0UHpuOC1{IN88[{9udC5? NUPkXJhFOjRxNEigbC=> NX;F[okxTUN3ME2xMlIh|rypL33M M1fR[lIzPTlzMki0
NCCIT  NHXRN|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfkfoJxOjEkgKOxOFDDqM7:Zz;tcC=> MnvMO|IhcA>? NFr5RYZNTDVyPUGyNOKh|rypL33sxsA> Mnf6NlI2PjJzNkC=
NCCIT  NVXuNXQ1TnWwY4Tpc44hSXO|YYm= NXvwRlU2PzJiaB?= NWnVdItVe2mpbnnmbYNidnSueTDpcoNz\WG|ZYOgZ4F{eGG|ZT2zJIFkfGm4aYT5xsA> NUjiUnRIOjJ3NkKxOlA>
NCCIT  NFW2[o9HfW6ldHnvckBCe3OjeR?= NWrVdVNjPzJiaB?= NYP0c5Q5e2mpbnnmbYNidnSueTDpcoNz\WG|ZYOgZ4F{eGG|ZT24JIFkfGm4aYT5xsA> M1Tsb|IzPTZ{MU[w
NCCIT  NXm1W4czTnWwY4Tpc44hSXO|YYm= MnfhO|IhcA>? M1ziZ5Nq\26rZnnjZY51dHliaX7jdoVie2W|IHPhd5Bie2VvOTDhZ5Rqfmm2edMg NWjVbllNOjJ3NkKxOlA>
NCCIT  NH7SNGNHfW6ldHnvckBCe3OjeR?= NYPxb3ZxPzJiaB?= M1vNT5Nq\26rZnnjZY51dHliaX7jdoVie2W|IFLBXEBt\X[nbB?= M33aV|IzPTZ{MU[w
NCCIT  NUfQNXJrTnWwY4Tpc44hSXO|YYm= NW\JbmRrPzJiaB?= NF\sSG1{cWewaX\pZ4FvfGy7IHTlZ5Jm[XOnczD0bIUhSmOuLUKgZ49vfGWwdB?= MXeyNlU3OjF4MB?=
NCCIT  NULW[2pjTnWwY4Tpc44hSXO|YYm= MkXOO|IhcA>? Momyd4lodmmoaXPhcpRtgSCmZXPy[YF{\XNidHjlJGN6fC2lIHzleoVt MWSyNlU3OjF4MB?=
HeLa Mlv5SpVv[3Srb36gRZN{[Xl? NWjXUJBLOzBxN{Cg{txoN22u MUSyOOKhcA>? NITJTIlqdmO{ZXHz[ZMhfGinIH3SUmEhdGW4ZXzzJI9nyqCyNURvwKxCXE1ucEKxxsBidmUEoFfBSGQ1PQ>? NHnO[4czOjR6N{mzOy=>
MCF-7  NX\TToc2TnWwY4Tpc44hSXO|YYm= NXvUfYxwOzBxN{Cg{txoN22u NYD0RWtrOjUEoHi= MUHpcoNz\WG|ZYOgeIhmKG2UTlGgcIV3\Wy|IH;mxsBxPTQxvJzBWG0teDJzwrDhcoTDqEeDRFS0OS=> NVLTWFJnOjJ2OEe5N|c>
HeLa M{C4dGN6fG:2b4jpZ4l1gSCDc4PhfS=> MW[zNE84OCEQvHevcYw> MYCyOOKhcA>? MVLpcoR2[2W|IHjp[4htgSC|aXfubYZq[2GwdDDs[ZZmdHNib3[g[pJi\22nboTl[EBFVkFicnXs[YF{\SCrboTvJJRp\SCleYTvdIxie21? M3PReVIzPDh5OUO3
MCF-7  M3\nNWN6fG:2b4jpZ4l1gSCDc4PhfS=> NFXaWY4{OC95MDFOwIcwdWx? NHPjRZAzPMLiaB?= NYTDXWZRcW6mdXPld{BpcWeqbImgd4lodmmoaXPhcpQhdGW4ZXzzJI9nKG[{YXft[Y51\WRiRF7BJJJmdGWjc3WgbY51dyC2aHWgZ5l1d3CuYYPt NIXRfJczOjR6N{mzOy=>
NT2 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWOxNFAuPjBywrFOwIcwdWx? NXHhU2xDOjRiaB?= NYTEZm9FUUN3ME20NFAhyrWpL33s NV\we4Y{OjJ2Nkm5OVI>
NT2 NW\VZmJlTnWwY4Tpc44hSXO|YYm= MYS0NFDDqM7:Zz;tcC=> NXK1THd5OjRiaB?= Mn;td4lodmmoaXPhcpRtgSCrbnPy[YF{\XNiY3HzdIF{\S1|LEisPUBi[3Srdnn0feKh NW\JU3VGOjJ2Nkm5OVI>
NT2 NVfZeHh2TnWwY4Tpc44hSXO|YYm= M3:4[lQxOMLizsznM41t NGnZb|kzPCCq MmTud4lodmmoaXPhcpRtgSCrbnPy[YF{\XNiQlHYJIxmfmWu NXq2WVFtOjJ2Nkm5OVI>
NT2 MVPGeY5kfGmxbjDBd5NigQ>? NVrZXmxFPDBywrFOwIcwdWx? NXfN[WcyOjRiaB?= Ml3od4lodmmoaXPhcpRtgSCmZXPy[YF{\XNiQnPsMVIhdGW4ZXy= MX6yNlQ3QTl3Mh?=
CHO M2raRWZ2dmO2aX;uJGF{e2G7 MlTENk42yqEQvHevcYw> NF3sdowyQCCqL{[g[C=> MkDLbY5lfWOnc9MgdIVze2m|dHXuZ4Uhd2ZiY3jyc41we2:vZTDkZY1i\2V? MmrtNlIzOzBzOUW=
Jurkat NVnwXoM{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHZNE0yODEEoN88[{9udA>? NVXS[mdiOjRiaB?= MWPhdpJme3S|IITo[UBk\WyuIHP5Z4xmKGG2IITo[UBIOiCyaHHz[S=> M{C2flIzOjJ|M{Oy
Jurkat M{mybmZ2dmO2aX;uJGF{e2G7 Mkm5N|DDqM7:Zz;tcC=> MkTINlQhcA>? MYnpcoNz\WG|ZYOgeIhmKHC{b4TlbY4hdGW4ZXzzJI9nKGO7Y3zpcpMhTDNuIFGgZY5lKEJz NVnMbIZnOjJ{MkOzN|I>
Jurkat NGD6Z2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInTelExNTFyMNMg{txoN22u MnnFNlQhcA>? MY\pcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36gbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYKge4l1cCCjbjDJR|UxKH[jbIXlJI9nKDFyMN88[{9uVA>? MXGyNlIzOzN|Mh?=
Jurkat NY[0T3VmTnWwY4Tpc44hSXO|YYm= M2rK[lMxyqEQvHevcYw> MljtNlQhcA>? M2T1VYlv[3KnYYPld{B1cGViZX\m[YN1KG:oIID5Z45q\GmxbnWgc44heGixc4Doc5J6dGG2aX;uJIxmfmWuczDv[kBpcXO2b37lJGgzSS6[ M13GXlIzOjJ|M{Oy
U2OS EGFPnls NITkdFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPpNE0zyqEQvHevcYw> NWXvc5d2OjRiaB?= NWixbodvcW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? MXmyNVgyOTByNx?=
U2OS KuEnls MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLwfGVpOC1{wrFOwIcwdWx? M{XOU|I1KGh? NHzXR4JqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 NWjRcFRzOjF6MUGwNFc>
MCF-7 NWG1UVhlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTtT4twOC12MECg{txO Ml6yO|IhcA>? MnvhUGM2OD1zNUGuPOKh|ryP Ml3mNlE4ODN{OUG=
MCF-7/Adr  M4na[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3JZXFCOC12MECg{txO MWC3NkBp NHnvN5VNSzVyPUW4MlXDqM7:TdMg MXqyNVcxOzJ7MR?=
WI-38 MYfGeY5kfGmxbjDBd5NigQ>? M4\sZlAwPDBxOEFihKnPxGdxbX|CpC=> MkizN{Bp M4rsN4lv\HWlZYOgZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDpcoNz\WG|ZTDpckB1cGViTV6g[pJmeXWnbnP5xsA> NGnJboQzOTV7OU[xNi=>
hBMSC M1rSbmZ2dmO2aX;uJGF{e2G7 NIXNV4cxNzRyL{iw5qCK|rypL33sxsA> MkHzN{Bp MYfpcoR2[2W|IHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRiaX7jdoVie2ViaX6geIhmKE2QIH\y[ZF2\W6ledMg NF3XUm0zOTV7OU[xNi=>
NCI-H23 MXXGeY5kfGmxbjDBd5NigQ>? M4G3TFAwPDBxOEFihKnPxGdxbX|CpC=> MoTtN{Bp M33Q[4lv\HWlZYOgZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDpcoNz\WG|ZTDpckB1cGViTV6g[pJmeXWnbnP5xsA> MVeyNVU6QTZzMh?=
A-549 NX7rN3NHTnWwY4Tpc44hSXO|YYm= M1niRlAwPDBxOEFihKnPxGdxbX|CpC=> MWqzJIg> NWHIfVVtcW6mdXPld{BiKGOxbnPlcpRz[XSrb36t[IVx\W6mZX70JIlv[3KnYYPlJIlvKHSqZTDNUkBnemWzdXXuZ5nDqA>? NXTXRXBnOjF3OUm2NVI>
PBL  MljWSpVv[3Srb36gRZN{[Xl? M2[1VVAwPDBxOEFihKnPxGdxbX|CpC=> MmXvN{Bp MVjpcoR2[2W|IHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRiaX7jdoVie2ViaX6geIhmKE2QIH\y[ZF2\W6ledMg M2j0[VIyPTl7NkGy
pol β −/− MnG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVGwMlI2NTJyMNMg{txoN22u M1\vNFI1yqCq NVjH[4dU\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JJdqfGhiaX7jdoVie2mwZzDjc45k\W62cnH0bY9ve8Li MWKyNVI2OTl2NB?=
pol β +/+ MlvIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfzNE4zPS1{MEFCpO69\y:vbB?= MUSyOOKhcA>? NEHmS3Zl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImge4l1cCCrbnPy[YF{cW6pIHPvcoNmdnS{YYTpc45{yqB? NIPwWW0zOTJ3MUm0OC=>
pol β −/− NVf0e2dmTnWwY4Tpc44hSXO|YYm= NFvncIgxNTJwNTFOwIcwdWx? M1PtcFIhcA>? Mlv2Z4F2e2W|IFTORUBl[W2jZ3W= NVPDbVhpOjF{NUG5OFQ>
pol β +/+ NGnNZoJHfW6ldHnvckBCe3OjeR?= MV6wMVIvPSEQvHevcYw> NIX0PXEzKGh? MV;jZZV{\XNiRF7BJIRidWGpZR?= NGL3SFkzOTJ3MUm0OC=>
pol β −/− MoS2SpVv[3Srb36gRZN{[Xl? NITVVYkxNTVizsznM41t NYfV[4NQPDhiaB?= M3znboNifXOnczDtbYNzd263Y3zleZMh\G:|ZTDhcoQhfGmvZTDk[ZBmdmSnboTsfS=> NWn3Rm55OjF{NUG5OFQ>
pol β +/+ NV22PXlzTnWwY4Tpc44hSXO|YYm= NFHxTmcxNTVizsznM41t MnzSOFghcA>? MVPjZZV{\XNibXnjdo9vfWOuZYXzJIRwe2ViYX7kJJRqdWViZHXw[Y5l\W62bIm= NH:2NGozOTJ3MUm0OC=>
TK6  NGrDRoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3W1c|I2NTF3MDFOwIcwdWx? Mk\vPVYhcA>? Mn[wbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> NU\nSIlMOjFyOEG0PFc>
TK6  sLUC+Apn1 NHz3e|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHse5d{OjVvMUWwJO69\y:vbB?= NHjjW|c6PiCq NImydWhqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 MV[yNVA5OTR6Nx?=
TK6 sAPE1+Apn1 NIDsO|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\BV2FMOjVvMUWwJO69\y:vbB?= NUGzSJh5QTZiaB?= M{TPVJNq\26rZnnjZY51dHliaX7obYJqfHNiY3XscEBoem:5dHig[I9{\SCmZYDlcoRmdnSueR?= NIqwNJYzOTB6MUS4Oy=>
HCT116 NYHUclF1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfkNlUuOTVyIN88[{9udA>? MYm5OkBp Mn\rbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> M1[3VlIyODhzNEi3
HCT116 sLUC+Apn1 NF7GZYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\zRZg{OjVvMUWwJO69\y:vbB?= NE\0eHU6PiCq NUmzZmpncW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? Mn\tNlExQDF2OEe=
HCT116 sAPE1+Apn1 NXjNfnNVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nX[FI2NTF3MDFOwIcwdWx? MXu5OkBp NXfGcFVQe2mpbnnmbYNidnSueTDpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 MoDJNlExQDF2OEe=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
LRP6 / Wnt5AB / Dvl2 / β-catenin; 

PubMed: 27649046     


CRL-1490 cells were treated with the indicated concentrations of bleomycin for either 12 or 24 h, and then probed for canonical Wnt proteins LRP6, Wnt5AB, Dvl2, and β-catenin. 

phospho-eIF2α / eIF2α; 

PubMed: 23762310     


Western blotting analysis of phosphorylated, total eIF2α and β-actin in CT26 treated 24 h with the indicated drugs. BLM: Bleomycin

cytochrome c; 

PubMed: 20154224     


mitochondrial release of cytochrome c was detected by Western blot in cytosolic extract and analyzed by band densitometry. Data show the means of four independent experiments ± SE. *Statistical significance from control, P < 0.05. Representative Western blots are shown.

Bcl-xl; 

PubMed: 20154224     


Representative Western blots are shown of whole cell extract using anti-Bcl-xL.

Bcl-2; 

PubMed: 20154224     


Representative Western blots are shown of whole cell extract using anti-Bcl-2.

27649046 23762310 20154224
Immunofluorescence
LC3; 

PubMed: 23762310     


CT26 cells were cultured on glass slides and treated with indicated drugs for 24 h. The cells were then submitted to anti-LC3 (green) and DAPI (blue) labeling and observed under an epifluorescence microscope. BLM: Bleomycin

23762310
ELISA
HMGB1; 

PubMed: 23762310     


HMGB1 was titrated with ELISA method in supernatant of CT26 cells treated 24 h with indicated drugs. BLM: Bleomycin

23762310
In vivo Day 7 post-Bleomycin sulfate, CD45+ cells in BALf in NOX-/- is 1.7-fold > WT, 57% of which are Mf that decreases by 67% in WT and 83% in NOX-/- by Day 21. [5]

Protocol

Cell Research:

[4]

+ Expand
  • Cell lines: ADIPO-P2 cells
  • Concentrations: 2.5 μg/mL
  • Incubation Time: 30 minutes
  • Method:

    ADIPO-P2 cells are grown in D-MEM high glucose medium supplemented with 20% fetal calf serum, penicillin (100 U/mL) and streptomycin (100 μg/mL) at 37 °C and 5% CO2 atmosphere. Cells are cultured as monolayer in TC25 Corning flasks containing 1.5 × 105 cells/mL. For each experiment, two flasks are set up, one for the control and one for the treated culture. During the log phase of growth ADIPO-P2 cells are treated with a 30 minutes pulse of 2.5 μg/mL of Bleomycin sulfate. Control cultures are set up in parallel but not exposed to Bleomycin sulfate. Time of exposure and concentration of Bleomycin sulfate are chosen according to previous studies carried out in our laboratory with mammalian cells exposed to Bleomycin sulfate. At the end of the pulse treatment with Bleomycin sulfate, the cells are washed twice with Hank's balanced salt solution and kept in culture with fresh culture medium until harvesting. Cells are continuously maintained in culture during 5 passages or subcultures after treatment. Subcultivation is carried out whenever the cultures became confluent (approximately 4 × 105 cells/mL of culture medium). To estimate cell growth, at the time of subcultivation cells are collected by trypsinization, an aliquot of about 200 μL stained with 0.4% trypan blue, and the number of viable cells is determined. Cells are then suspended in fresh culture medium and dispensed into new culture flasks containing 1 × 105 cells/mL to continue growing. The rest of the cells is discarded or dispensed in another flask for cytogenetic analysis, which is performed at 18 hours and 10 days after the end of treatments. To analyze chromosomal aberrations, colchicine (0.1 μg/mL) is added to cell cultures during the last 3 hours of culture. Chromosome preparations are made following standard procedures. After harvesting, cells are hypotonically shocked, fixed in methanol:acetic acid (3:1), spread onto glass slides and processed for PNA-FISH. Two independent experiments are carried out.


    (Only for Reference)
Animal Research:

[7]

+ Expand
  • Animal Models: CD-1 mice
  • Formulation: Saline
  • Dosages: 5 mg/kg, 2 ml/kg
  • Administration: Administered via i.t.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL warmed (66.11 mM)
Water 100 mg/mL (66.11 mM)
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
Saline
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 1512.62
Formula

C55H85N17O25S4

CAS No. 9041-93-4
Storage powder
in solvent
Synonyms NSC125066

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03596918 Recruiting AIDS-Related Kaposi Sarcoma|Human Immunodeficiency Virus 1 Positive AIDS Malignancy Consortium|National Cancer Institute (NCI)|The EMMES Corporation|University of Arkansas|University of California Los Angeles October 10 2018 Phase 1
NCT03596918 Recruiting AIDS-Related Kaposi Sarcoma|Human Immunodeficiency Virus 1 Positive AIDS Malignancy Consortium|National Cancer Institute (NCI)|The EMMES Corporation|University of Arkansas|University of California Los Angeles October 10 2018 Phase 1
NCT03067181 Recruiting Adult Germ Cell Tumor|Childhood Extracranial Germ Cell Tumor|Childhood Germ Cell Tumor|Extragonadal Embryonal Carcinoma|Grade 2 Immature Ovarian Teratoma|Grade 3 Immature Ovarian Teratoma|Malignant Germ Cell Tumor|Stage I Ovarian Choriocarcinoma|Stage I Ovarian Embryonal Carcinoma|Stage I Ovarian Teratoma|Stage I Ovarian Yolk Sac Tumor|Stage I Testicular Choriocarcinoma AJCC v6 and v7|Stage I Testicular Embryonal Carcinoma AJCC v6 and v7|Stage I Testicular Yolk Sac Tumor AJCC v6 and v7|Stage II Ovarian Choriocarcinoma|Stage II Ovarian Embryonal Carcinoma|Stage II Ovarian Yolk Sac Tumor|Stage II Testicular Choriocarcinoma AJCC v6 and v7|Stage II Testicular Embryonal Carcinoma AJCC v6 and v7|Stage II Testicular Yolk Sac Tumor AJCC v6 and v7|Stage III Ovarian Choriocarcinoma|Stage III Ovarian Embryonal Carcinoma|Stage III Ovarian Yolk Sac Tumor|Stage III Testicular Choriocarcinoma AJCC v6 and v7|Stage III Testicular Embryonal Carcinoma AJCC v6 and v7|Stage III Testicular Yolk Sac Tumor AJCC v6 and v7|Stage IV Ovarian Choriocarcinoma|Stage IV Ovarian Embryonal Carcinoma|Stage IV Ovarian Yolk Sac Tumor|Testicular Mixed Choriocarcinoma and Embryonal Carcinoma|Testicular Mixed Choriocarcinoma and Teratoma|Testicular Mixed Choriocarcinoma and Yolk Sac Tumor Children''s Oncology Group|National Cancer Institute (NCI) May 8 2017 Phase 3
NCT03067181 Recruiting Adult Germ Cell Tumor|Childhood Extracranial Germ Cell Tumor|Childhood Germ Cell Tumor|Extragonadal Embryonal Carcinoma|Grade 2 Immature Ovarian Teratoma|Grade 3 Immature Ovarian Teratoma|Malignant Germ Cell Tumor|Stage I Ovarian Choriocarcinoma|Stage I Ovarian Embryonal Carcinoma|Stage I Ovarian Teratoma|Stage I Ovarian Yolk Sac Tumor|Stage I Testicular Choriocarcinoma AJCC v6 and v7|Stage I Testicular Embryonal Carcinoma AJCC v6 and v7|Stage I Testicular Yolk Sac Tumor AJCC v6 and v7|Stage II Ovarian Choriocarcinoma|Stage II Ovarian Embryonal Carcinoma|Stage II Ovarian Yolk Sac Tumor|Stage II Testicular Choriocarcinoma AJCC v6 and v7|Stage II Testicular Embryonal Carcinoma AJCC v6 and v7|Stage II Testicular Yolk Sac Tumor AJCC v6 and v7|Stage III Ovarian Choriocarcinoma|Stage III Ovarian Embryonal Carcinoma|Stage III Ovarian Yolk Sac Tumor|Stage III Testicular Choriocarcinoma AJCC v6 and v7|Stage III Testicular Embryonal Carcinoma AJCC v6 and v7|Stage III Testicular Yolk Sac Tumor AJCC v6 and v7|Stage IV Ovarian Choriocarcinoma|Stage IV Ovarian Embryonal Carcinoma|Stage IV Ovarian Yolk Sac Tumor|Testicular Mixed Choriocarcinoma and Embryonal Carcinoma|Testicular Mixed Choriocarcinoma and Teratoma|Testicular Mixed Choriocarcinoma and Yolk Sac Tumor Children''s Oncology Group|National Cancer Institute (NCI) May 8 2017 Phase 3
NCT02166463 Recruiting Ann Arbor Stage IIB Hodgkin Lymphoma|Ann Arbor Stage IIIB Hodgkin Lymphoma|Ann Arbor Stage IV Hodgkin Lymphoma|Ann Arbor Stage IVA Hodgkin Lymphoma|Ann Arbor Stage IVB Hodgkin Lymphoma|Childhood Hodgkin Lymphoma|Classic Hodgkin Lymphoma National Cancer Institute (NCI) March 16 2015 Phase 3
NCT02166463 Recruiting Ann Arbor Stage IIB Hodgkin Lymphoma|Ann Arbor Stage IIIB Hodgkin Lymphoma|Ann Arbor Stage IV Hodgkin Lymphoma|Ann Arbor Stage IVA Hodgkin Lymphoma|Ann Arbor Stage IVB Hodgkin Lymphoma|Childhood Hodgkin Lymphoma|Classic Hodgkin Lymphoma National Cancer Institute (NCI) March 16 2015 Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    what is the ratio between bleomycin A2 and bleomycin B2 in your product?

  • Answer:

    The content of Bleomycin A2 and Bleomycin B2 is 62% and 29% respectively.

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products0

Tags: buy Bleomycin Sulfate | Bleomycin Sulfate ic50 | Bleomycin Sulfate price | Bleomycin Sulfate cost | Bleomycin Sulfate solubility dmso | Bleomycin Sulfate purchase | Bleomycin Sulfate manufacturer | Bleomycin Sulfate research buy | Bleomycin Sulfate order | Bleomycin Sulfate mouse | Bleomycin Sulfate chemical structure | Bleomycin Sulfate mw | Bleomycin Sulfate molecular weight | Bleomycin Sulfate datasheet | Bleomycin Sulfate supplier | Bleomycin Sulfate in vitro | Bleomycin Sulfate cell line | Bleomycin Sulfate concentration | Bleomycin Sulfate nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID